184 results on '"Urosevic, Jelena"'
Search Results
2. Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
3. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
4. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
5. Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells.
6. Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors
7. The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
8. Mechanism by which Aurora B inhibitors promotes RB and p53-dependent senescence.
9. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
10. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
11. The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance
12. Supplementary Figure 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
13. Data from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
14. Supplementary Figure 3 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
15. Supplementary Figure 2 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
16. Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
17. Supplementary Figure 4 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
18. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
19. Abstract 6272: AZ-PRMT5i-1: A potent MTAP-selective PRMT5 inhibitor with pharmacodynamic and monotherapy anti-tumor activity in MTAP-deleted tumours
20. Figure S1, Figure S2, Figure S3 from Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
21. Data from ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer
22. Supplementary Materials and Methods from ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer
23. Supplementary Figures and Tables from ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer
24. Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors
25. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
26. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis
27. Identification of NOG as a Specific Breast Cancer Bone Metastasis-supporting Gene
28. Abstract 1141: Pharmacokinetic and pharmacodynamic evaluation of human tumor xenograft models treated upon administration of trastuzumab deruxtecan
29. Abstract 2642: BID expression levels determine cell fate upon AURKB inhibition
30. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome
31. Organ-specific metastases
32. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
33. RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation
34. Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
35. Amplification of 22q11 is associated with hypersensitivity to AURKB inhibition in cell line models of resistance to EGFR TKIs
36. Changes in ABC Transporter Expression during Hematopoiesis Cause Lineage-Biased Cytopenias in Patients Treated with Aurora Kinase Inhibitors
37. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
38. Additional file 2 of VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
39. Additional file 1 of VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
40. Abstract 1020: Amplification of 22q11 is associated with hypersensitivity to AURKB inhibition in cell line models of resistance to EGFR TKIs
41. Abstract 1107: Precision phosphoproteomic analysis in Chr22q11.2 amplified NSCLC cells reveals distinct signaling corruption and response to Aurora kinase B inhibition
42. Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor
43. ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer
44. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
45. Using cells devoid of RAS proteins as tools for drug discovery
46. Severe central nervous system thrombotic events in hemoglobin Sabine patient
47. Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML
48. Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)
49. Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis
50. Stratification and therapeutic potential of PML in metastatic breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.